HZNP - Horizon Pharma Public Limited Company

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Horizon Pharma Public Limited Company

Connaught House
1st Floor 1 Burlington Road
Dublin 4
Ireland
353 1 772 2100
http://www.horizonpharma.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees990

Key Executives

NameTitlePayExercisedYear Born
Mr. Timothy P. WalbertChairman, Pres & CEON/AN/A1967
Mr. Paul W. HoelscherExec. VP & CFON/AN/A1965
Mr. Barry J. MozeExec. VP & Chief Admin. Officer977.54kN/A1954
Ms. Irina KonstantinovskyExec. VP & Chief HR Officer514.53kN/A1970
Mr. Miles W. McHughChief Accounting Officer & Sr. VPN/AN/A1965
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients. Its products also include KRYSTEXXA to treat chronic refractory gout; RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; PENNSAID 2% to treat pain of osteoarthritis of the knees; DUEXIS for the treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis; VIMOVO to treat signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; and MIGERGOT for the treatment of vascular headache. The company has collaboration agreement with Fox Chase Cancer Center to evaluate ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer; Alliance for Lupus Research to evaluate RAYOS/LODOTRA on the fatigue experienced by systemic lupus erythematosus patients; and Syneos Health, Inc. in connection with its Phase III confirmatory trial to evaluate teprotumumab for the treatment of thyroid eye disease. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Corporate Governance

Horizon Pharma Public Limited Company’s ISS Governance QualityScore as of November 1, 2018 is 4. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 8; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.